Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constanze C Schmies

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Frontiers in Pharmacology|October 5, 2020
Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase InhibitorsLaura Schäkel, Constanze C Schmies, Riham M Idris, et al.
Cellular and Molecular Life Sciences : CMLS|February 25, 2022
CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicityKarolina Losenkova, Akira Takeda, Symantas Ragauskas, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Fluorescent Probes for Ecto-5'-nucleotidase (CD73)Constanze C Schmies, Georg Rolshoven, Riham M Idris, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 14, 2025
Design, development and evaluation of a tritium-labeled radiotracer for ecto-5'-nucleotidase (CD73) - A versatile research tool and diagnostic agent for personalized medicineRiham M Idris, Haneen Al-Hroub, Constanze C Schmies, et al.
Journal of Medicinal Chemistry|May 1, 2026
Nucleotide-Derived Competitive Inhibitors of Ectonucleotidase CD39─A Promising Extracellular Target for Immunotherapy of CancerChunyang Bi, Florian Schwermer, Laura Schäkel, et al.
Angewandte Chemie (International Ed. in English)|March 16, 2026
Fluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5'-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid TumorsClemens Dobelmann, Constanze C Schmies, Georg Wilhelm Rolshoven, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Frontiers in Pharmacology|October 5, 2020
Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase InhibitorsLaura Schäkel, Constanze C Schmies, Riham M Idris, et al.
Cellular and Molecular Life Sciences : CMLS|February 25, 2022
CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicityKarolina Losenkova, Akira Takeda, Symantas Ragauskas, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Fluorescent Probes for Ecto-5'-nucleotidase (CD73)Constanze C Schmies, Georg Rolshoven, Riham M Idris, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 14, 2025
Design, development and evaluation of a tritium-labeled radiotracer for ecto-5'-nucleotidase (CD73) - A versatile research tool and diagnostic agent for personalized medicineRiham M Idris, Haneen Al-Hroub, Constanze C Schmies, et al.
Journal of Medicinal Chemistry|May 1, 2026
Nucleotide-Derived Competitive Inhibitors of Ectonucleotidase CD39─A Promising Extracellular Target for Immunotherapy of CancerChunyang Bi, Florian Schwermer, Laura Schäkel, et al.
Angewandte Chemie (International Ed. in English)|March 16, 2026
Fluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5'-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid TumorsClemens Dobelmann, Constanze C Schmies, Georg Wilhelm Rolshoven, et al.
Pageof 1